CA1303986C - Action anti-proliferative des arn double brin sur les tumeurs - Google Patents

Action anti-proliferative des arn double brin sur les tumeurs

Info

Publication number: CA1303986C
Authority: CA; Canada
Prior art keywords: ifn; cells; interferon; dsrna; cancer
Prior art date: 1985-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA 486814

Other languages

English (en)

Inventor

William Alvin Carter

Paul O.P. Ts'o

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HEM Pharmaceuticals Corp

Johns Hopkins University

Original Assignee

HEM Pharmaceuticals Corp

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-15

Filing date

1985-07-15

Publication date

1992-06-23

1985-07-15 Application filed by HEM Pharmaceuticals Corp, Johns Hopkins University filed Critical HEM Pharmaceuticals Corp

1985-07-15 Priority to CA 486814 priority Critical patent/CA1303986C/fr

1992-06-23 Application granted granted Critical

1992-06-23 Publication of CA1303986C publication Critical patent/CA1303986C/fr

Status Expired legal-status Critical Current

Links

210000004881 tumor cell Anatomy 0.000 title abstract description 32
230000001028 anti-proliverative effect Effects 0.000 title abstract description 24
210000004027 cell Anatomy 0.000 claims abstract description 134
206010028980 Neoplasm Diseases 0.000 claims abstract description 96
201000011510 cancer Diseases 0.000 claims abstract description 68
108010050904 Interferons Proteins 0.000 claims abstract description 59
102000014150 Interferons Human genes 0.000 claims abstract description 59
239000000203 mixture Substances 0.000 claims abstract description 33
238000011282 treatment Methods 0.000 claims abstract description 33
230000001225 therapeutic effect Effects 0.000 claims abstract description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 93
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 92
229940079322 interferon Drugs 0.000 claims description 56
241000282414 Homo sapiens Species 0.000 claims description 52
238000002560 therapeutic procedure Methods 0.000 claims description 31
229940025294 hemin Drugs 0.000 claims description 22
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 10
230000035755 proliferation Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 8
238000000338 in vitro Methods 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
102000003996 Interferon-beta Human genes 0.000 claims description 4
108020004511 Recombinant DNA Proteins 0.000 claims description 4
108090000467 Interferon-beta Proteins 0.000 claims description 3
238000005516 engineering process Methods 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims 4
102000006992 Interferon-alpha Human genes 0.000 claims 2
108010047761 Interferon-alpha Proteins 0.000 claims 2
102000008070 Interferon-gamma Human genes 0.000 claims 1
108010074328 Interferon-gamma Proteins 0.000 claims 1
229940044627 gamma-interferon Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 24
230000007547 defect Effects 0.000 abstract description 23
239000000126 substance Substances 0.000 abstract description 21
230000002195 synergetic effect Effects 0.000 abstract description 7
229940047124 interferons Drugs 0.000 abstract description 3
230000004663 cell proliferation Effects 0.000 abstract description 2
-1 ribose nucleic acids Chemical class 0.000 abstract description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 abstract 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102100040019 Interferon alpha-1/13 Human genes 0.000 description 138
230000000694 effects Effects 0.000 description 76
210000000822 natural killer cell Anatomy 0.000 description 32
210000005170 neoplastic cell Anatomy 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
239000002609 medium Substances 0.000 description 15
230000012010 growth Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
150000002500 ions Chemical class 0.000 description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
230000006698 induction Effects 0.000 description 12
241000282412 Homo Species 0.000 description 11
230000004069 differentiation Effects 0.000 description 11
201000010099 disease Diseases 0.000 description 11
230000001988 toxicity Effects 0.000 description 11
231100000419 toxicity Toxicity 0.000 description 11
230000000259 anti-tumor effect Effects 0.000 description 10
238000012937 correction Methods 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
230000000840 anti-viral effect Effects 0.000 description 7
238000003556 assay Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
208000032839 leukemia Diseases 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000004820 blood count Methods 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000000411 inducer Substances 0.000 description 6
230000002147 killing effect Effects 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
230000036210 malignancy Effects 0.000 description 6
210000001167 myeloblast Anatomy 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 5
230000009471 action Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
230000002265 prevention Effects 0.000 description 5
230000001737 promoting effect Effects 0.000 description 5
238000005070 sampling Methods 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
230000003321 amplification Effects 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
230000003416 augmentation Effects 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000005741 malignant process Effects 0.000 description 4
238000010606 normalization Methods 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000243 solution Substances 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000012190 activator Substances 0.000 description 3
239000008272 agar Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000003915 cell function Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
230000009422 growth inhibiting effect Effects 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
239000002799 interferon inducing agent Substances 0.000 description 3
210000003887 myelocyte Anatomy 0.000 description 3
238000011275 oncology therapy Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000007747 plating Methods 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
229960003087 tioguanine Drugs 0.000 description 3
208000030218 transient fever Diseases 0.000 description 3
230000004565 tumor cell growth Effects 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
206010006002 Bone pain Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
241001625930 Luria Species 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241000711408 Murine respirovirus Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
230000008512 biological response Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000013043 chemical agent Substances 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000008274 immunosurveillance mechanism Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
210000001237 metamyelocyte Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008672 reprogramming Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010004231 Bence Jones proteinuria Diseases 0.000 description 1
206010051779 Bone marrow toxicity Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101150031358 COLEC10 gene Proteins 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
102100024206 Collectin-10 Human genes 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000002738 Giemsa staining Methods 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 1
101000999325 Homo sapiens Cobalamin binding intrinsic factor Proteins 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
241000011102 Thera Species 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010817 Wright-Giemsa staining Methods 0.000 description 1
241000289690 Xenarthra Species 0.000 description 1
SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
230000001064 anti-interferon Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
231100000366 bone marrow toxicity Toxicity 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
230000008711 chromosomal rearrangement Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011337 individualized treatment Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000007434 lytic lesion Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
QBQQKHZEHKZMJF-NXUSYKNTSA-N mioe Chemical compound C=1([C@@H]2OC(=O)C[C@@H]3[C@@]2(C)CC[C@H]2C3=C[C@@H]3[C@@H](OC(=O)C(C)C)C(C)(C)[C@@H]([C@@]2(C)C3=O)CC(=O)OC)C=COC=1 QBQQKHZEHKZMJF-NXUSYKNTSA-N 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000004719 natural immunity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108010043671 prostatic acid phosphatase Proteins 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
241000894007 species Species 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 486814 1985-07-15 1985-07-15 Action anti-proliferative des arn double brin sur les tumeurs Expired CA1303986C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 486814 CA1303986C (fr)	1985-07-15	1985-07-15	Action anti-proliferative des arn double brin sur les tumeurs

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 486814 CA1303986C (fr)	1985-07-15	1985-07-15	Action anti-proliferative des arn double brin sur les tumeurs

Publications (1)

Publication Number	Publication Date
CA1303986C true CA1303986C (fr)	1992-06-23

Family

ID=4130981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 486814 Expired CA1303986C (fr)	1985-07-15	1985-07-15	Action anti-proliferative des arn double brin sur les tumeurs

Country Status (1)

Country	Link
CA (1)	CA1303986C (fr)

1985
- 1985-07-15 CA CA 486814 patent/CA1303986C/fr not_active Expired

Legal Events

Date	Code	Title	Description
2009-06-23	MKLA	Lapsed
2012-12-05	MKEC	Expiry (correction)	Effective date: 20121205

Publication	Publication Date	Title
EP0113162B1 (fr)	1989-07-19	Effet antinéoplastiques des acides ds-ribonucléiques sur les cellules des tumeurs
Maluish et al.	1983	Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Balkwill et al.	1984	Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system
Dollinger et al.	1967	Analogs of 1-β-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies
CA1320446C (fr)	1993-07-20	Modulation d'etats cellulaires resistant a la lymphokine a l'aide de dsarn
US6911435B1 (en)	2005-06-28	Method of treating leukopenia with adenosine
PT87997B (pt)	1995-03-01	Processo para a preparacao de composicoes farmaceuticas uteis para a correccao de vias metabolicas aberrantes associadas com ciclos de crescimento descontrolados de celulas tumorais e de virus contendo arn de dupla cadeia
HUP0300219A2 (hu)	2003-06-28	L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
Cooper et al.	1987	Interferons in the treatment of multiple myeloma
EP0225759A2 (fr)	1987-06-16	Compositions d'interféron
Burke et al.	1970	A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC 63878)
CA1303986C (fr)	1992-06-23	Action anti-proliferative des arn double brin sur les tumeurs
Lotzová et al.	1984	Stimulation of NK cell cytotoxic potential of normal donors by two species of recombinant alpha interferon
Kobayashi et al.	1994	A phase I study of intermittent infusion cladribine in patients with solid tumors
AU2002336864A1 (en)	2003-07-10	Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
Visani et al.	2004	Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?
Priestman	1983	Interferons and cancer therapy
Lea et al.	1972	Action of Miracil D and related compounds on DNA and RNA synthesis in regenerating liver and hepatomas
US8217014B2 (en)	2012-07-10	Pharmaceutical composition for treatment of blood clotting disorder
Papac et al.	1962	CLINICAL EVALUATION OF THE PYRIMIDINE NUCLEOSIDES 5-FLUORO-2'-DEOXYURIDINE AND 5-IODO-2'-DEOXYURIDINE1, 2, 3
US5175005A (en)	1992-12-29	Method of controlling lung tumor cell metastasis
Reiter et al.	1993	Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation
Balmer	1990	Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part I. The Interferons
Bruntsch et al.	1984	Lack of response in nine patients with breast cancer treated with fibroblast interferon
Gutterman	1984	Clinical investigation of interferons: status summary and prospects for the future